pink2 → green1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
Not yet reviewed: this article is pending editorial review by Lyrea.
WARNINGREDOSING CAN TRIGGER PSYCHOSIS
PCP-like dissociatives can cause mania, paranoia, or psychosis that outlasts the high. High doses, redosing, and sleep loss raise the risk.
3-Cl-PCP
3-Chlorophencyclidine
3-Chloro-PCP
3-Cl-PCP is a novel dissociative substance of the arylcyclohexylamine class that produces dissociative, hallucinogenic, and euphoric effects.citation needed First identified in Slovenia in December 2020, it emerged alongside other novel dissociatives such as 3-F-PCP and DMXE. It exhibits comparable potency to phencyclidine with a slightly distinct pharmacological profile, being somewhat more potent as an NMDA antagonist.1 Its effects include dose-dependent dissociative anesthesia.citation needed
Dosage & Duration
Dosage & Duration not written up yet
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
3-Cl-PCP produces a dissociative experience broadly comparable to phencyclidine, with a potency in the same range as its parent compound. As with other PCP-type arylcyclohexylamines, the experience centers on a progressive sense of detachment from the body and surroundings, though its precise effects profile is reported to differ somewhat from PCP itself. Detailed subjective documentation of this compound remains limited.
Physical
Physical effects follow the dissociative pattern of diminishing bodily awareness and connection at higher doses.
Cognitive
The headspace is dissociative in character, marked by a growing sense of detachment from thought and environment as the dose increases.
See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives
Pharmacology
Pharmacodynamics
3-Cl-PCP acts principally as an NMDA receptor antagonist. Compared to PCP, it is somewhat more potent at the NMDA receptor while retaining comparable potency as a dopamine reuptake inhibitor.1
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
DepressantsStimulants
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
With extended or repeated 3-Cl-PCP use, tolerance is believed to emerge for many effects, so larger amounts may be needed to produce comparable results.
Baseline Reset
1-2 weeks
Half Tolerance
4-7 days
Cross Tolerance
Dissociatives
Harm Potential
Addiction & Dependence
Psychological
ModerateEarly reports suggest 3-Cl-PCP is likely moderately addictive with habit-forming properties that may exceed those of other dissociatives such as ketamine, MXE, and DCK. Compulsive redosing is reported, particularly via smoked or vaporized routes of administration.citation needed
Physical
Cravings and withdrawal effects may occur upon cessation after chronic use, though specific physical withdrawal symptoms have not been characterized.
Toxicity
Cardiovascular
Reports suggest 3-Cl-PCP produces cardiovascular effects including abnormal heartbeat, elevated blood pressure, and increased heart rate during intoxication, with sensations of cardiovascular strain as if the body is working harder to metabolize the substance; these effects appear more prominent than with related dissociatives.
Respiratory
Respiratory depression has been reported as a physical effect and may present increased risk at higher doses.
Urinary System
Repeated and excessive use over extended periods may cause bladder and urinary tract problems similar to ketamine-induced cystitis, though likely to a lesser extent due to the higher potency requiring smaller amounts of substance to be consumed.
Psychosis Risk
Reports suggest a high potential for adverse psychological effects including psychosis and delusions. Risk appears elevated with chronic use or at higher doses.citation needed
Seizure Risk
Seizures may occur in individuals predisposed to them, especially in physically taxing conditions such as dehydration, fatigue, or malnourishment. The extent to which seizures occur at typical doses remains unknown.
History & Culture
3-Cl-PCP is a novel dissociative from the arylcyclohexylamine class that emerged as part of a wave of designer drugs in the early 2020s. It was first identified in Slovenia in December 2020, marking its initial appearance on the recreational drug market.…
Legality
By Country
Illegal3
HungaryIllegal78/2022. (XII. 28.) BM rendelet az ellenőrzött anyagokról, current consolidated text dated 29 June 2026, 3. melléklet (Új pszichoaktív anyagok jegyzéke), 6.1 table row 251; 2025. évi XIX. törvény §§ 26-27 and 40 (effective 15 June 2025); current 2012. évi C. törvény (Btk.) §§ 176, 178, 180, 184, 459(1a) and 461, consolidated 26 August 2026.456
Current Hungarian law does not merely rely on a generic analogue theory: 3-Cl-PCP is individually named in Annex 3 point 6.1, and Btk. §459(1a) expressly treats Annex 3 substances as kábítószer for the relevant criminal provisions. Unauthorized possession, acquisition, production, import, export or transit is therefore covered by Btk. §178; offering, transfer, placing on the market or dealing is covered by §176; and §184 is the residual conduct-specific offense where no other offense applies.
SwitzerlandIllegal (analog/blanket ban)Betäubungsmittelverzeichnisverordnung (BetmVV-EDI; SR 812.121.11), Annex 6 Verzeichnis e item 291 Arylcyclohexylamine (consolidated standing 13 March 2026); Betäubungsmittelkontrollverordnung (BetmKV; SR 812.121.1), Articles 3(2)(e), 5(2) and 11(1)789
3-Cl-PCP's identity is 1-[1-(3-chlorophenyl)cyclohexyl]piperidine: a phenylcyclohexylamine derivative with an aromatic chlorine substituent and piperidine nitrogen, matching the structural alternatives in binding BetmVV-EDI Annex 6 Verzeichnis e item 291. The substance is not separately named but is captured by the generic Swiss structural rule. Verzeichnis e is not the same as a Verzeichnis-d prohibited-substances listing: BetmKV Article 3(2)(e) describes raw materials/products with presumed narcotic-like effects subject to Verzeichnis-a control measures, and the item 291 text exempts industrial and scientific use while expressly not exempting private use. The applicable framework provides controlled coverage and authorization requirements without establishing an unqualified criminal prohibition for every possible act.
Controlled / restricted1
References
Source Pages
Citations
- Valeria Catalani, Davide Arillotta, John Martin Corkery, Amira Guirguis, Alessandro Vento, & Fabrizio Schifano. (2020). Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.63240512
- Neue-psychoaktive-Stoffe-Gesetz (NpSG) — Anlage 1, Stoffgruppe 6: Von Arylcyclohexyl(methyl)amin abgeleitete Verbindungen. (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG) — § 3 Unerlaubter Umgang mit neuen psychoaktiven Stoffen. (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
- 78/2022. (XII. 28.) BM rendelet az ellenőrzött anyagokról, current consolidated text. njt.jog.gov.hu (n.d.). https://njt.jog.gov.hu/jogszabaly/2022-78-20-0A1
- 2025. évi XIX. törvény a kábítószer előállításának, használatának, terjesztésének, népszerűsítésének tilalmával összefüggő törvénymódosításokról. njt.jog.gov.hu (n.d.). https://njt.jog.gov.hu/jogszabaly/2025-19-00-00.01
- 2012. évi C. törvény a Büntető Törvénykönyvről, current consolidated text. njt.jog.gov.hu (n.d.). https://njt.jog.gov.hu/jogszabaly/2012-100-00-001
- Betäubungsmittelverzeichnisverordnung (BetmVV-EDI), Annex 6 Verzeichnis e item 291, consolidated text standing 13 March 2026. fedlex.admin.ch (n.d.). https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/363/20260313/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-363-20260313-de-pdf-a-3.pdf1
- Betäubungsmittelkontrollverordnung (BetmKV), Articles 3(2)(e), 5(2) and 11(1), consolidated text standing 23 January 2023. fedlex.data.admin.ch (n.d.). https://fedlex.data.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2011/362/20230123/de/pdf-a/fedlex-data-admin-ch-eli-cc-2011-362-20230123-de-pdf-a.pdf1
- Swissmedic, Listen und Verzeichnisse, section 4.1 Betäubungsmittel und Vorläuferstoffe. swissmedic.ch (n.d.). https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html1
- Psychoactive Substances Act 2016, Section 2 — Meaning of 'psychoactive substance'. (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/21
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-Cl-PCP article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
![Wait. Where’d you say we were headed? [dissociatives replication]](https://dosewiki-media.gremblinzuwu.workers.dev/media/sha256/6f/6f5ea0975ee38ebece682dad6d74e78c1a98fee999d8269c64b0747ac301c0a7.webp)